Myovant Sciences Operating Income 2017-2022 | MYOV
Myovant Sciences operating income from 2017 to 2022. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Myovant Sciences Annual Operating Income
(Millions of US $) |
| 2022 |
$-187 |
| 2021 |
$-261 |
| 2020 |
$-275 |
| 2019 |
$-265 |
| 2018 |
$-141 |
| 2017 |
$-56 |
| 2016 |
$-2 |
Myovant Sciences Quarterly Operating Income
(Millions of US $) |
| 2022-03-31 |
$-52 |
| 2021-12-31 |
$-60 |
| 2021-09-30 |
$-18 |
| 2021-06-30 |
$-57 |
| 2021-03-31 |
$-77 |
| 2020-12-31 |
$-78 |
| 2020-09-30 |
$-72 |
| 2020-06-30 |
$-34 |
| 2020-03-31 |
$-64 |
| 2019-12-31 |
$-78 |
| 2019-09-30 |
$-67 |
| 2019-06-30 |
$-65 |
| 2019-03-31 |
$-72 |
| 2018-12-31 |
$-69 |
| 2018-09-30 |
$-64 |
| 2018-06-30 |
$-60 |
| 2018-03-31 |
$-47 |
| 2017-12-31 |
$-42 |
| 2017-09-30 |
$-30 |
| 2017-06-30 |
$-22 |
| 2017-03-31 |
$-23 |
| 2016-12-31 |
$-9 |
| 2016-09-30 |
$-7 |
| 2016-06-30 |
$-17 |
| 2016-03-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.313B |
$0.231B |
|
Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.
|
